Reviva reports third quarter 2024 financial results and recent business highlights

– 108 patients have completed 1-year of treatment in 1-year open-label extension (ole) trial – – vocal biomarker speech latency data from recover trial reinforce brilaroxazine's improvement on negative symptoms and other key symptom domains of schizophrenia – – topline data from ole trial expected in december 2024 – cupertino, calif., nov. 14, 2024 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), inflammatory and cardiometabolic diseases, today reported financial results for the third quarter ended september 30, 2024 and summarized recent business highlights.
RVPH Ratings Summary
RVPH Quant Ranking